Efficacy of DNA hypomethylating capacities of 5-aza-2′-deoxycytidine and its alpha anomer

被引:19
作者
Fojtova, Miloslava
Piskala, Alois
Votruba, Ivan
Otmar, Miroslav
Bartova, Eva
Kovarik, Ales
机构
[1] Acad Sci Czech Republ, Inst Biophys, CS-61265 Brno, Czech Republic
[2] Acad Sci Czech Republ, Inst Organ Chem & Biochem, CR-16610 Prague 6, Czech Republic
关键词
DNA methylation; hypomethylation drug; 5-aza-2 '-deoxycytidine; anomers; cancer;
D O I
10.1016/j.phrs.2006.09.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this paper, we have compared hypomethylating ability of classical beta-D-anomer of 5-aza-2'-deoxycytidine (5-aza-CdRf) and its alpha anomer in cell cultures. Alpha anomers of nucleosides generally exhibit low biological activity compared to their beta counterparts. It is reported that alpha anomer of 5-aza-CdRf efficiently hypomethylated genomic DNA in human T-lymphoblastoid CCRF-CEM cells. Satellite 2 and 18S rDNA were hypomethylated by alpha anomer at concentrations comparable to the beta form. However, the toxicity of the alpha anomer was 4-fold less than that of beta form. Contrast to CCRF-CEM the A549 lung carcinoma cells, possessing negligible level of methylation at repetitive loci, were highly resistant to 5-aza-CdRf treatment suggesting that global genomic methylation might be needed to mediate cytotoxic effect of the drug. Possible mechanisms of inhibition of DNA methylation by alpha anomer are discussed. In conclusion, alpha anomer of 5-aza-CdRf displaying lower host cytotoxicity than the classical beta form may be of potential use in epigenetic therapy. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:16 / 22
页数:7
相关论文
共 38 条
  • [1] Effect of trichostatin a and 5′-azacytidine on transgene reactivation in U937 transduced cells
    Bartoli, A
    Fettucciari, K
    Fetriconi, I
    Rosati, E
    Di Ianni, M
    Tabilio, A
    Delfino, DV
    Rossi, R
    Marconi, P
    [J]. PHARMACOLOGICAL RESEARCH, 2003, 48 (01) : 111 - 118
  • [2] Nuclear levels and patterns of histone H3 modification and HP1 proteins after inhibition of histone deacetylases
    Bártová, E
    Pacherník, J
    Harnicarová, A
    Kovarík, A
    Kovaríková, M
    Hofmanová, J
    Skalníková, M
    Kozubek, M
    Kozubek, S
    [J]. JOURNAL OF CELL SCIENCE, 2005, 118 (21) : 5035 - 5046
  • [3] DNA methylation as a target for drug design
    Bender, CM
    Zingg, JM
    Jones, PA
    [J]. PHARMACEUTICAL RESEARCH, 1998, 15 (02) : 175 - 187
  • [4] Bender CM, 1998, CANCER RES, V58, P95
  • [5] BOUCHARD J, 1983, MOL PHARMACOL, V24, P109
  • [6] Epigenetic targets in hematopoietic malignancies
    Claus, R
    Lübbert, M
    [J]. ONCOGENE, 2003, 22 (42) : 6489 - 6496
  • [7] CREUSOT F, 1982, J BIOL CHEM, V257, P2041
  • [8] Genomic imprinting - Primer
    da Rocha, ST
    Ferguson-Smith, AC
    [J]. CURRENT BIOLOGY, 2004, 14 (16) : R646 - R649
  • [9] On the biological significance of DNA methylation
    Doerfler, W
    [J]. BIOCHEMISTRY-MOSCOW, 2005, 70 (05) : 505 - 524
  • [10] DNA methylation and cancer therapy: new developments and expectations
    Esteller, M
    [J]. CURRENT OPINION IN ONCOLOGY, 2005, 17 (01) : 55 - 60